News Releases

Product-related press releases will be removed from our website within three weeks after publication. Press releases are made available for the media and to comply with applicable rules and regulations they are removed from our website. Previous press releases can be provided upon request. Please contact us here.

Year

November 29, 2023

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

November 20, 2023

Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism

November 15, 2023

Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA

November 7, 2023

Ascendis Pharma Reports Third Quarter 2023 Financial Results

October 31, 2023

Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission

October 26, 2023

Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023

October 16, 2023

Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023

October 2, 2023

Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting

September 23, 2023

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

September 15, 2023

Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 10 of 35